Aclaris Therapeutics, Inc. (ACRS) vs Fulgent Genetics, Inc. (FLGT)

A side-by-side comparison of Aclaris Therapeutics, Inc. and Fulgent Genetics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ACRS vs FLGT

growth of $100 · dividends reinvested · last 10y
ACRS -83.0% (-16.2%/yr)FLGT +125.6% (+8.5%/yr)FLGT compounded faster over this window
Log scale — wide-divergence pair
1101001k10kStart $10020182020202220242026$17$226
ACRS FLGT

ACRS vs FLGT: by the numbers

  • •FLGT is the larger company ($638M vs $589M market cap).
  • •Both run net losses; FLGT's is the smaller (-26.05% vs -921.50% net margin).
  • •ACRS grew revenue faster over the past five years (4.39% vs -18.66% CAGR).

Metrics side by side

Valuation

MetricACRSFLGT
P/S ratio71.711.97
P/B ratio4.730.64

Profitability

MetricACRSFLGT
Gross margin73.28%35.58%
Operating margin-975.91%-28.23%
Net margin-921.50%-26.05%
ROE-60.79%-8.42%
ROIC-56.99%-11.80%

Growth (annualized)

MetricACRSFLGT
Revenue CAGR (5Y)4.39%-18.66%
Total return CAGR (5Y)-24.23%-22.38%

Frequently asked

Which has grown faster, ACRS or FLGT?
Over the past five years, ACRS grew revenue faster — ACRS at a 4.39% CAGR versus FLGT at -18.66%.
How have ACRS and FLGT total returns compared?
Over the past 10 years, ACRS delivered -16.23% and FLGT delivered 8.90% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.